top of page

Technologies Promoting Heart Recovery

World’s First Minimally Invasive Non-blood Contacting
Cardiac Assist Device to Treat Acute Heart Failure.

With a lead investment from Wellcome Trust, CorInnova is developing a minimally invasive, non-blood contacting cardiac assist device for acute heart failure treatment.  The device is intended to initially treat the large and fast-growing short-term cardiac assist market (up to 7 days’ use). It will expand this market to an $8B addressable market by treating the 50% of patients who cannot use, or are unsuitable for, existing cardiac assist devices. The device is collapsible allowing it to be delivered and secured to the heart in a minimally invasive manner. The device conforms to the heart’s surface, and gently compresses the heart to increase cardiac output using an external pneumatic driver that operates in synchrony with the heartbeat.

The device increases cardiac output without touching the blood, thereby eliminating the risk of thrombosis and stroke due to device blood contact, the need for anti-coagulants, the risk of bleeding, and the risk of kidney dysfunction or damage.

News & Press Releases
Awards, Recognition, Investments

_____

R.8d73502099f94ef12ea16324c561bc31.png

Global financial services firm

BTIG features CorInnova in its “Highlighting Private Companies Across the Medical Technology and Digital Health Landscape – Vol. 35.” February 29, 2024

December 9.jpg

Dr. George Letsou presents CorInnova's preclinical data at CSI Focus D-HF Congress in Frankfurt, Germany

phonto 3.jpg

Reviews in Cardiovascular Medicine: The CorInnova Implantable Cardiac Assist System for Direct Cardiac Compression

phonto 3.jpg

CorInnova joins MedTech Innovator's 2022 Cohort in Tenth Year of World’s Largest MedTech Accelerator Program

November 5.jpg

William Altman presents at TCT 2021 session "Emerging Technological Trends III: Interventional Heart Failure and Neuromodulation Therapies"

IMG_1B5229567181-1.jpeg

CorInnova invited to speak at CSI D-HF Device Therapies for Heart Failure in Frankfurt

IMG_83B457CF6CB7-1.jpeg

CorInnova wins “Most Promising Life Science Company” award from Rice Alliance for Technology and Entrepreneurship at Texas Life Science Forum

_____

image001[100].png

2024 Rising Star

2024 Medical Device Company to Watch

MedTech Inn logo.png
Welcomme sm bw.jpeg
JLABS.png
TechFW.png
AngelMD
NSF logo_nsf2.jpg

2020, 2019 National Science Foundation Grant Awards

ACA box logo.png
TMC
MedCity logo.png
MedTech Inn logo.png

2019 Finalist Medtech Innovator Competition West Coast Round

Screen Shot 2017-10-16 at 5.34.54 PM.png
gBETAlogo.png
RESI Small logo.jpeg
HTA Logo.png

2018 Health Tech Austin Medical Device Showcase Competition

sharktank.jpg
Screen Shot 2017-10-16 at 5.38.47 PM.png
Screen Shot 2017-10-16 at 5.37.21 PM.png
TCT CRF logo.jpg

TCT Interventional Innovation and Best Technical Concepts in Interventional Heart Failure

US Pat Seal.png

US Patent Office 18 Granted Patents

Screen Shot 2017-10-16 at 5.52.51 PM.png

NIH STTR Fast Track Phase I/II Grant Award

Investments

TETF.jpg
TMC Venture Logo.png
HAN logo.png
K4 Logo.png
SCAN logo.jpg
Cowtown logo.jpg
Acadiana logo.jpg

Texas Emerging Technology Fund

Texas Medical Center

TMC Venture Fund

Houston Angel Network

​

Keiretsu Forum

South Coast Angel Network

Cowtown Angels

Acadiana Angels

​

Kyto logo.jpg

KYTO Technology

& Life Sciences

HBSAANY.jpg

Harvard Business School

Alumni Angels of Greater

New York

AVP FastTrak Fund

Screen Shot 2023-03-15 at 11.17.37 AM.png

None of the statements or information contained on our website is an offer to buy or sell our securities.  Offers to buy or sell our securities are made only pursuant to separate formal legal agreements. Nor should you make any investment decision based on the information on our website, but solely on that information contained in such legal agreements.

bottom of page